512 related articles for article (PubMed ID: 19948947)
21. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
Desai NR; Canestaro WJ; Kyrychenko P; Chaplin D; Martell LA; Brennan T; Matlin OS; Choudhry NK
Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):694-9. PubMed ID: 24192573
[TBL] [Abstract][Full Text] [Related]
22. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.
Grosdidier C; Quilici J; Loosveld M; Camoin L; Moro PJ; Saut N; Gaborit B; Pankert M; Cohen W; Lambert M; Beguin S; Morange PE; Bonnet JL; Alessi MC; Cuisset T
Am J Cardiol; 2013 Apr; 111(7):985-90. PubMed ID: 23340030
[TBL] [Abstract][Full Text] [Related]
23. Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel.
Nishiya Y; Hagihara K; Ito T; Tajima M; Miura S; Kurihara A; Farid NA; Ikeda T
Drug Metab Dispos; 2009 Mar; 37(3):589-93. PubMed ID: 19047469
[TBL] [Abstract][Full Text] [Related]
24. Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel.
Small DS; Farid NA; Payne CD; Konkoy CS; Jakubowski JA; Winters KJ; Salazar DE
Clin Pharmacokinet; 2010 Dec; 49(12):777-98. PubMed ID: 21053990
[TBL] [Abstract][Full Text] [Related]
25. Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.
Floyd CN; Passacquale G; Ferro A
Clin Pharmacokinet; 2012 Jul; 51(7):429-42. PubMed ID: 22568693
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.
Reese ES; Daniel Mullins C; Beitelshees AL; Onukwugha E
Pharmacotherapy; 2012 Apr; 32(4):323-32. PubMed ID: 22461122
[TBL] [Abstract][Full Text] [Related]
27. [Prasugrel, a new thienopyridine].
Schrör K; Huber K
Hamostaseologie; 2007 Dec; 27(5):351-5. PubMed ID: 18060245
[TBL] [Abstract][Full Text] [Related]
28. The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.
Panattoni L; Brown PM; Te Ao B; Webster M; Gladding P
Pharmacoeconomics; 2012 Nov; 30(11):1067-84. PubMed ID: 22974536
[TBL] [Abstract][Full Text] [Related]
29. Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel.
Chen CH; Yang JC; Uang YS; Lin CJ
Biopharm Drug Dispos; 2012 Jul; 33(5):278-83. PubMed ID: 22623337
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
Dobesh PP
Pharmacotherapy; 2009 Sep; 29(9):1089-102. PubMed ID: 19698014
[TBL] [Abstract][Full Text] [Related]
31. [Antiplatelet therapy in coronary heart disease. Some problems and achivements].
Gratsianskiĭ NA
Kardiologiia; 2010; 50(6):4-21. PubMed ID: 20659022
[TBL] [Abstract][Full Text] [Related]
32. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects.
Farid NA; Small DS; Payne CD; Jakubowski JA; Brandt JT; Li YG; Ernest CS; Salazar DE; Konkoy CS; Winters KJ
Pharmacotherapy; 2008 Dec; 28(12):1483-94. PubMed ID: 19025429
[TBL] [Abstract][Full Text] [Related]
33. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.
Jakubowski JA; Winters KJ; Naganuma H; Wallentin L
Cardiovasc Drug Rev; 2007; 25(4):357-74. PubMed ID: 18078435
[TBL] [Abstract][Full Text] [Related]
34. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D
Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027
[TBL] [Abstract][Full Text] [Related]
35. [Extent of platelet aggregation inhibition and clinical events: new evidence with prasugrel].
Abbate R; Crea F; De Servi S; Filippi E; Gensini GF; Golinos P; Savonitto S
G Ital Cardiol (Rome); 2010 Feb; 11(2):127-37. PubMed ID: 20408476
[TBL] [Abstract][Full Text] [Related]
36. Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability.
Ancrenaz V; Daali Y; Fontana P; Besson M; Samer C; Dayer P; Desmeules J
Curr Drug Metab; 2010 Oct; 11(8):667-77. PubMed ID: 20942779
[TBL] [Abstract][Full Text] [Related]
37. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
38. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A
J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250
[TBL] [Abstract][Full Text] [Related]
39. Prasugrel: a novel antiplatelet agent.
Riley AB; Tafreshi MJ; Haber SL
Am J Health Syst Pharm; 2008 Jun; 65(11):1019-28. PubMed ID: 18499874
[TBL] [Abstract][Full Text] [Related]
40. Prasugrel for the treatment of patients with acute coronary syndrome.
Marzot F; Pengo V
Vasc Health Risk Manag; 2009; 5(1):321-4. PubMed ID: 19436677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]